Filtering by:
ImmunotherapyNew Treatment for Neuroblastoma Is in Early-Stage Trials
American Cancer Society grantee Andras Heczey, MD, is trying to adapt the technique known as CAR T-cell therapy to cure children with neuroblastoma by using natural killer T cells. He's trying the treatment for the first time in children in a phase 1 clinical trial.
Recent Advances in Lung Cancer Treatment Resulting in Lower Death Rates
According to a new study, death rates from non-small cell lung cancer have fallen sharply in recent years, mostly due to advances in treatment.
FDA Approves First Drug for Cancers with a High Tumor Mutational Burden
The US Food and Drug Administration (FDA) has expanded the approval of the immunotherapy drug pembrolizumab (Keytruda) to include any cancer with a high tumor mutational burden (TMB-H).
FDA Approves Padcev (Enfortumab vedotin-ejfv) for Bladder Cancer
The US Food and Drug Administration (FDA) has approved a new type of drug for certain people with bladder cancer.
2019 in Review: New Cancer Drug Approvals
In 2019, the FDA approved several new drug treatments for different cancer types. Here are the stories that made headlines on cancer.org this year.
FDA Approves Keytruda (Pembrolizumab) for Head and Neck Cancer
The US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line treatment for people with advanced head and neck cancer.
FDA Approves Tecentriq (Atezolizumab) for Small Cell Lung Cancer
The US Food and Drug Administration (FDA) has approved the immunotherapy drug Tecentriq (atezolizumab) for the treatment of small cell lung cancer (SCLC).
FDA Approves Immunotherapy for Breast Cancer
The US Food and Drug Administration today approved the first immunotherapy treatment for breast cancer. It approved a combination of Tecentriq (atezolizumab) and Abraxane (nab-paclitaxel) for people with advanced triple negative breast cancer.
